AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06653465
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline, a kind of crystalloid widely used in clinical treatment.
Trial: NCT06648265
Drug: Tranexamic Acid (Topical)
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Add 250 mg of TXA per liter of Klein\&#39;s Tumescent solution for arm liposculpture
Trial: NCT05827042
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive intravenous alteplase (0.9mg/kg, maximum 90mg) or tenecteplase (0.25mg/kg, maximum 25mg) before endovascular thrombectomy.
Trial: NCT00673751
Drug: GLP-2
RxNorm normalized name: (Gly2)GLP-2
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 450 nmol subcutaneous
Trial: NCT06503783
Drug: BL-M17D1
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Trial: NCT06130579
Drug: IFN-Α
RxNorm normalized name: IFN-α
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukemia-associated immunophenotyping (LAIPs) was performed by flow cytometry at +1 month and +2 month after HSCT. If MRD was negative on two consecutive flow cytometry assays, interferon-α prophylaxis was initiated on day +75 after transplantation, and cyclosporine was tapered on day +100 after transplantation. The dose of interferon-α was 3 million units/time, subcutaneously injected twice a week. Cycles were given every 4 weeks until hematologic relapse or up to 6 cycles.
Trial: NCT06620029
Drug: BMX-001
RxNorm normalized name: BMX-001 free base
DrugBank: BMX-001 free base (DB17516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMX-001 consists of a porphyrin ring with pyridyl groups attached at each of the four methane bridge carbons. The nitrogen in the pyridyl ring is at the 2 position and has a side chain consisting of six carbons with an ether linkage. A manganese atom is chelated into the porphyrin ring and is the active center of the molecule. This molecule is an enzymatic scavenger of free radical species operating at close to diffusion-limited rates. BMX-001 (7-28 mg) will be given by subcutaneous (s.c.) injection starting on Day 1, Day 8, Day 15, and Day 22 of each 28-day PTX treatment cycle.
Trial: NCT06620029
Drug: Paclitaxel (Taxol)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel will be given via IV infusion at a dose = 80 mg/m2 on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle and will be sourced from standard commercial sources. Appropriate pretreatment prior to PTX will be given as per institutional standards. PTX management for any adverse event (AE) in any cycle, reasonably attributed to the chemotherapy agent that requires dose interruption should be managed per package insert, and/or institutional guidelines. Dose modification recommendations are provided in protocol to provide general consistency with dosing. Study Treatment dosing BMX-001 should continue even if the PTX is omitted. The subject may continue on PTX if the AE does not prohibit dosing per institutional practice. Grade 3 or higher infusion PTX reactions or recurrent infusion reactions may require permanent discontinuation of PTX. PTX may be continued in select patients using institutional desensitization protocol.
Trial: NCT06159491
Drug: Pacritinib
RxNorm normalized name: Pacritinib
DrugBank: Pacritinib (DB11697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will take Pacritinib 100 mg - 200mg BID for each 28 day cycle
Trial: NCT06159491
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine 75mg/m\^2 will be administered IV or SQ QD D1-7 of each 28 day cycle
Trial: NCT05283135
Drug: risankizumab
RxNorm normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Risankizumab (Skyrizi) is an anti-IL-23 antibody being investigated for the treatment of multiple inflammatory diseases, including psoriasis, Crohn's disease, ulcerative colitis, and psoriatic arthritis.
Trial: NCT06062602
Drug: TAK-676
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral microdose injection by the CIVO device.
Trial: NCT06062602
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intratumoral microdose injection by the CIVO device.
Trial: NCT06062602
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intratumoral microdose injection by the CIVO device.
Trial: NCT06062602
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intratumoral microdose injection by the CIVO device.
Trial: NCT05890352
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05890352
Drug: Tazemetostat
RxNorm normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT05890352
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT06004856
Drug: Orelabrutinib
RxNorm normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orelabrutinib once daily (QD)
Trial: NCT05718843
Drug: BI 425809
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 425809
Trial: NCT05807659
Drug: fractionated busulfan-based conditioning regimen
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug: Chidamide 30 mg oral twice weekly for 2 weeks Drug: Fludarabine 35 mg/m2 intravenously daily for 5 days in the 2nd week Drug: Cytarabine~1 g/m2 intravenously for 5 days in the 2nd week Drug: Busulfan 3.2 mg/kg intravenously daily for 2 days in the 1st week, 1.6 mg/kg intravenously daily for 4 days in the 2nd week Procedure/Surgery: allogeneic hematopoietic stem cell transplantation
Trial: NCT00002059
Drug: Inosine pranobex
RxNorm normalized name: inosine pranobex
DrugBank: Inosine pranobex (DB13156)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04713592
Drug: Placebo for Risankizumab
RxNorm normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous (SC) Injection
Trial: NCT04713592
Drug: Risankizumab
RxNorm normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous (SC) Injection
Trial: NCT06512207
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitor
Trial: NCT06664138
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam is a recently approved medication used for the induction of general anesthesia and maintenance of sedation. There have been no prior studies using remimazolam for the induction of anesthesia in ECT, and this research aims to investigate the feasibility of using remimazolam as an induction agent for ECT.
Trial: NCT06664138
Drug: Etomidate
RxNorm normalized name: Etomidate
DrugBank: Etomidate (DB00292)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etomidate is widely used in ECT due to its rapid onset, stable hemodynamic profile, and quick recovery. In this study, remimazolam will be used as the experimental group, while etomidate will serve as the control group.
Trial: NCT06451562
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a local anesthetic drug of the amino amide type
Trial: NCT06667024
Drug: Hyperbaric bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received the standard spinal anesthesia with 0.5% 3 ml according to the patient hyperbaric bupivacaine only
Trial: NCT06667024
Drug: Dexmedetomidine and Hyperbaric bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received dexmedetomidine 4 μg and 0.5% (3-4 ml according to the patient height) hyperbaric bupivacaine
Trial: NCT06174298
Drug: Granulocyte Colony-Stimulating Factor (Filgrastim)
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intervention Group Fresh Embryo Transfers: On day 5 or 6 of culture, viable embryos will be transferred into a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the embryo transfer (ET) procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.~Intervention Group Frozen Embryo Transfers: Cryopreserved embryos will be thawed according to the Kitazato thawing protocol and will be subsequently transferred to a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the ET procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.
Trial: NCT05640726
Drug: PD-1
RxNorm normalized name: NPD-1
DrugBank: PD-168393 (DB07662)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
Trial: NCT05640726
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive bevacizumab，5mg/kg，intravenously over 60 - 90 minutes, day 1 of every 2 weeks
Trial: NCT05640726
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive Oxaliplatin，85mg/m2，day1
Trial: NCT05640726
Drug: Calcium folinate
RxNorm normalized name: Calcium folinate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive calcium folinate ，400mg/m2，day1
Trial: NCT05640726
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive 5-fluorouracil ，400mg/m2，day1
Trial: NCT05098119
Drug: Sintilimab, Nab-paclitaxel, Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant Therapy
Trial: NCT05098119
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant Therapy
Trial: NCT05848492
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole will be given for prevention of invasive candidiasis in preterm and very low birthweight babies.
Trial: NCT05848492
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.9% Saline 2cc intravenous will be given to preterm babies in placebo group.
Trial: NCT05581303
Drug: Olpasiran
RxNorm normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olpasiran given by subcutaneous injection Q12W.
Trial: NCT05413369
Drug: Insulin glargine/Lixisenatide
RxNorm normalized name: INSULIN GLARGINE/LIXISENATIDE
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: solution, by subcutaneous injection
Trial: NCT05413369
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet, orally
Trial: NCT05413369
Drug: SGLT2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, orally
Trial: NCT05431023
Drug: Lactoferrin
RxNorm normalized name: Lactoferrin
DrugBank: Lactoferrin (DB16555)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactoferrin binds to and blocks glycosaminoglycan viral receptors, especially heparan sulfate (HS). The binding of LF and HS prevents the first contact between virus and host cell and therefore prevents the infection
Trial: NCT06613854
Drug: Oral semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide Oral Tablets will be introduced to the Oral Semaglutide Arm as per protocol for regular therapy introduction.
Trial: NCT06613854
Drug: Empagliflozin 10 mg
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin Oral Tablets will be introduced to the Empagliflozin Arm as per protocol for regular therapy introduction.
Trial: NCT06016010
Drug: USL
RxNorm normalized name: USL-311
DrugBank: USL-311 (DB15265)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg of Achyranthis Radix Extract
Trial: NCT04738097
Drug: Ticagrelor 90mg
RxNorm normalized name: TICAGRELOR 90MG TAB
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASA 325 mg stat and ticagrelor 180 mg stat, then ASA 80 mg daily and ticagrelor 90 mg BID for 21 days.Treatment will be continue with ASA 80 until 3 months.
Trial: NCT04738097
Drug: Clopidogrel 75 mg
RxNorm normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ASA 325 mg stat and clopidogrel 300 mg stat, then ASA 80 mg and clopidogrel 75 mg daily for 21 days.Treatment will be continue with ASA 80 until 3 months.
Trial: NCT06698666
Drug: Sertraline Pill
RxNorm normalized name: sertraline Pill
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both control and intervention group will receive the sertraline as a standard therapy
Trial: NCT06699394
Drug: Teclistamab (Tec)
RxNorm normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teclistamab is administered subcutaneously with the usual step-up dosing: 0.06 mg/kg at day 1, 0.3 mg/kg at day 4, 1.5 mg/kg at day 8, and then 1.5 mg/kg weekly.
Trial: NCT05743101
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent.Endovascular thrombectomy is one of the treatments for acute ischemic stroke.
Trial: NCT05743101
Drug: Levofloxacin simulant
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin simulant is placebo.Endovascular thrombectomy is one of the treatments for acute ischemic stroke.
Trial: NCT00063791
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00000861
Drug: Indinavir sulfate
RxNorm normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05300802
Drug: Dexmedetomidine Hcl 100 Mcg/mL Inj
RxNorm normalized name: dexmedeTOMIDine HCl 100 MCG/ML Injectable Solution
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mcg/kg diluted DEX will be added to the priming solution and followed by a continuous infusion of 50 ml Ringer acetate running at 25 ml/hour.
Trial: NCT05300802
Drug: Dexmedetomidine Hcl 100 Mcg/mL Inj
RxNorm normalized name: dexmedeTOMIDine HCl 100 MCG/ML Injectable Solution
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.5 mcg/kg DEX will be added to the priming solution and followed by a continuous infusion of 0.25 mcg/kg/hour DEX diluted in 50 ml of ringer acetate running at 25 ml/hour.
Trial: NCT06065813
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Toripalimab intravenously every 3 weeks 3 doses of Toripalimab before operation 14 doses of Toripalimab 30 days after operation
Trial: NCT06631521
Drug: Darolutamide
RxNorm normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 600 mg (two 300 mg tablets) taken orally twice daily.
Trial: NCT06631521
Drug: Relugolix
RxNorm normalized name: Relugolix
DrugBank: Relugolix (DB11853)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A loading dose of 360 mg on the first day, followed by 120 mg taken orally once daily.
Trial: NCT06554509
Drug: SHR-1819 injection
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1819 injection
Trial: NCT05453435
Drug: Entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients enrolled in the study will accept entecavir prophylaxis that initiates within 1 week before the first course of CD20 monoclonal antibody therapy, and continues until 6 months after completing CD20 monoclonal antibody therapy.
Trial: NCT06111196
Drug: Recombinant Humanized Anti-PD-1 Monoclonal Antibody Solution for Injection
RxNorm normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100mg/4ml;single dose;intravenous injection
Trial: NCT06111196
Drug: Pembrolizumab injection
RxNorm normalized name: pembrolizumab Injection
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100mg/4ml;single dose;intravenous injection
Trial: NCT05484349
Drug: Tizanidine Hydrochloride
RxNorm normalized name: Tizanidine Hydrochloride
DrugBank: Tizanidine (DB00697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tizanidine Hydrochloride 1 mg Tid for 12 consecutive weeks and were followed up for 12 weeks
Trial: NCT05484349
Drug: Tizanidine Hydrochloride
RxNorm normalized name: Tizanidine Hydrochloride
DrugBank: Tizanidine (DB00697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tizanidine Hydrochloride 2 mg Tid for 12 consecutive weeks and were followed up for 12 weeks
Trial: NCT05484349
Drug: Tizanidine Hydrochloride Placebo
RxNorm normalized name: Tizanidine Hydrochloride
DrugBank: Tizanidine (DB00697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tizanidine Hydrochloride Placebo Comparator 1 tablet Tid for 12 consecutive weeks and were followed up for 12 weeks
Trial: NCT06152497
Drug: H1 blockade: Telfast: 180mg Fexofenadine
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H1 blockade: oral blockade with 180mg Fexofenadine
Trial: NCT06684951
Drug: hCG
RxNorm normalized name: HCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: observe hCG effect on endometrial receptivity
Trial: NCT05127304
Drug: Furoate/Umeclidinium/Vilanterol
RxNorm normalized name: Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furoate/Umeclidinium/Vilanterol
Trial: NCT05127304
Drug: Tiotropium Bromide/Olodaterol
RxNorm normalized name: tiotropium bromide/olodaterol HCl 2.5 mcg-2.5 mcg/actuation INHALATION MIST INHALER (GRAM)
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium Bromide/Olodaterol
Trial: NCT04784988
Drug: EHL-FVIII
RxNorm normalized name: factor VIII
DrugBank: Antihemophilic factor, human recombinant (DB00025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prophylaxis with EHL-FVIII targeting a 12% FVIII through level based on PK assessment with WAPPS-Hemo
Trial: NCT04784988
Drug: FVIII concentrate
RxNorm normalized name: factor VIII
DrugBank: Antihemophilic factor, human recombinant (DB00025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard prophylaxis with FVIII concentrate according to current guidelines
Trial: NCT06140888
Drug: Ginkgo Biloba Extract
RxNorm normalized name: Ginkgo biloba extract
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract 8 pills three times per day is administrated.
Trial: NCT04021121
Drug: LZD
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LZD 1200 mg daily
Trial: NCT04021121
Drug: High dose RIF
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIF 35 mg/kg/day
Trial: NCT05423197
Drug: 89Zr-panitumumab IV
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will be given a bolus of 1.0 mCi (range 0.8 - 1.2 mCi) of 89Zr-panitumumab before undergoing further standard of care diagnostic evaluation of the lesions
Trial: NCT05423197
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab 30mg will be given orally
Trial: NCT05104801
Drug: sitravatinib
RxNorm normalized name: Sitravatinib
DrugBank: Sitravatinib (DB15036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sitravatinib 100mg QD PO
Trial: NCT05104801
Drug: tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tislelizumab 200mg Q3W IV
Trial: NCT06419543
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Observe the incidence of paradoxical reactions after the first induction.